Session » Epidemiology & Public Health Poster II

Date: Sunday, November 17, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 1000

Adalimumab Biosimilar-to-biosimilar Switch in Patients with Inflammatory Rheumatic Diseases – Real-world Evidence from the Nationwide Danish Registry, DANBIO

10:30AM-12:30PM: Abstract Number: 0980

Ambient Air Pollution and Initiation of bDMARDs in Newly Diagnosed Rheumatoid Arthritis: A Nested Case-Control Study of NIH All of Us Cohort

10:30AM-12:30PM: Abstract Number: 0988

Antinuclear Antibody Positivity and Its Diagnostic Implications for Rheumatic Diseases in Dermatology Patients: A Comprehensive Single Center Analysis

10:30AM-12:30PM: Abstract Number: 0976

Assessment of Current Trends in Demographic and Clinical Characteristics of Male Patients with Rheumatoid Arthritis in North India

10:30AM-12:30PM: Abstract Number: 0994

Association Between Cardiovascular Risk Factors and the Onset of Giant Cell Arteritis: A Systematic Review and Meta-analysis

10:30AM-12:30PM: Abstract Number: 1003

Association Between Metabolic Markers and Knee Osteoarthritis: A Cross-sectional Study Using the Korea National Health and Nutrition Examination Survey 2009 to 2013

10:30AM-12:30PM: Abstract Number: 1006

Associations Between Rheumatic Diseases and Mental Health Disorders

10:30AM-12:30PM: Abstract Number: 0978

Associations of Fire Smoke and Other Pollutants with Incident Rheumatoid Arthritis and Rheumatoid Arthritis-Associated Interstitial Lung Disease

10:30AM-12:30PM: Abstract Number: 0999

Clinical and Biological Features of VEXAS Syndrome in Women: Study of 9 French Cases Compared with 263 Men

10:30AM-12:30PM: Abstract Number: 0991

Comparing the Prevalence of Sarcoidosis in Canadian Rural, Urban, and Farming Populations

10:30AM-12:30PM: Abstract Number: 0987

Correlates of Depression in Individuals with Chronic Fatigue Syndrome

10:30AM-12:30PM: Abstract Number: 1007

Demographic, Social, and Disease Factors Associated with Interstitial Lung Disease and Disease-Related Death in Dermatomyositis

10:30AM-12:30PM: Abstract Number: 1002

Depression Screening in Patients with Rheumatologic Diseases in a Large Tertiary Care Center

10:30AM-12:30PM: Abstract Number: 0997

Geographic and Lifestyle Exposures in Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1008

Immune Responses to Infection and Autoimmune Diseases in the UK Biobank

10:30AM-12:30PM: Abstract Number: 1009

Immunogenicity of the Recombinant Zoster Vaccine in People with Rheumatoid Arthritis Using Abatacept

10:30AM-12:30PM: Abstract Number: 0983

Life Satisfaction in Adults Living with Arthritis – a Cross-Sectional Analysis of the 2022 National Health Interview Survey

10:30AM-12:30PM: Abstract Number: 0989

Malignancy Risk Between JAK Inhibitors and Anti-TNF Therapy Across Disease Indications: A Bayesian Network Meta-analysis

10:30AM-12:30PM: Abstract Number: 0996

Myocarditis Following Pfizer-BioNTech BNT162b2 Vaccine: Epidemiology and Predisposition

10:30AM-12:30PM: Abstract Number: 0974

Number of Days Between Prior Low-dose Weekly Methotrexate Administration and S1-RBD Antibody Response in Adults with Immune Mediated Inflammatory Diseases Vaccinated Against COVID-19: Secondary Analysis of the Vaccine Response On-Off Methotrexate (VROOM) Study Data

10:30AM-12:30PM: Abstract Number: 1001

Perceived Mistreatment in Patients with Rheumatic Diseases: The Impact of the Underlying Diagnosis

10:30AM-12:30PM: Abstract Number: 1005

Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS) Events of Tofacitinib and Upadacitinib

10:30AM-12:30PM: Abstract Number: 0984

Predicting Risk of Infection in Hospitalized Patients with Rheumatic Diseases from the MIMIC-IV Clinical Database: A Machine Learning Approach

10:30AM-12:30PM: Abstract Number: 0990

Predictors of Adverse Events and Complications in Cirrhotic Patients with Rheumatoid Arthritis: A Nationwide Analysis

10:30AM-12:30PM: Abstract Number: 1004

Predictors of Post-acute Sequelae of COVID-19 in Patients with Rheumatoid Arthritis: A Retrospective Analysis of a Large Health System in the Midwestern United States

10:30AM-12:30PM: Abstract Number: 0975

Prevalence and Management of Patients with Comorbidities and Frailty in New Onset Polymyalgia Rheumatica

10:30AM-12:30PM: Abstract Number: 0993

Pulmonary Complications and Mortality Trends in Rheumatoid Arthritis Patients Aged 65 and Older in the United States: A CDC WONDER Database Analysis

10:30AM-12:30PM: Abstract Number: 0985

Specific Causes for Hospitalization in Persons with Inflammatory Arthritis Conditions and Gout: A Systematic Review

10:30AM-12:30PM: Abstract Number: 0986

State-and-County-Level Social Vulnerability Index and Trends in Systemic Lupus Erythematosus-Related Mortality in the U.S

10:30AM-12:30PM: Abstract Number: 0981

The Causal Effect of Sex Hormone-related Drugs on the Risk of Osteoarthritis – A Mendelian Randomization Study

10:30AM-12:30PM: Abstract Number: 0979

The Joint Project: A Community-Based, Barangay Health Worker-Led Screening Program for Childhood Musculoskeletal Disorders in a Barangay in San Pedro, Laguna, Philippines

10:30AM-12:30PM: Abstract Number: 1010

Total Cost Risk Scores and Barrier Categories in Patients with Axial Spondyloarthritis and Associated Factors

10:30AM-12:30PM: Abstract Number: 0998

Trends and Disparities in Cardiovascular Deaths in Systemic Lupus Erythematosus: A Population-Based Retrospective Study in the United States from 1999 to 2021

10:30AM-12:30PM: Abstract Number: 0982

Urinary Incontinence Among Individuals with Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1011

Use of the Shingrix Vaccine Among Patients with Inflammatory Arthritis and Risk of Cardiovascular Events Following Herpes Zoster

10:30AM-12:30PM: Abstract Number: 0977

Vaccine Effectiveness and Safety of Recombinant Zoster Vaccine (RZV) in Rheumatoid Arthritis (RA) Patient Populations Aged 50 Years and Older

10:30AM-12:30PM: Abstract Number: 0992

Visceral Adipose Tissue Measured by DXA Predicts Metabolic Syndrome in Low-Income Community-Dwelling Elderly: Insights from the São Paulo Ageing & Health (SPAH) Study

10:30AM-12:30PM: Abstract Number: 0995

What Is the Carbon Footprint of Adalimumab Originator and Its Various Biosimilar Drugs?

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].